文献速递放疗物理与技术姑息放疗与转移瘤

某州级多专科医疗系统在肿瘤治疗模式前8个绩效期内放射治疗支出情况

Radiation Therapy Expenditures Through the First 8 Performance Periods of the Oncology Care Model at a Statewide Multispecialty Health System.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-11-23

研究利用某州级多专科医疗系统在肿瘤治疗模式(OCM)前8个绩效期(2016年7月1日至2020年6月30日)的真实数据,分析放射治疗(RT)分次与费用的趋势。共识别9898例患者的17157次诊疗,其中2033例接受RT的2219次诊疗用于放射肿瘤(RO)费用分析。每次诊疗平均RT分次从PP1的19.2降至PP8的18.6。

要点

  • 每次诊疗平均RO支出PP1为6314美元 vs PP8为6664美元(P趋势>.05),按CPI调整后从6314美元降至6215美元。
  • 每次诊疗平均RT分次从PP1的19.2降至PP8的18.6,乳腺癌(-2.1)、肺癌(-2.8)和女性泌尿生殖系统肿瘤(-3.5)下降最明显。

核心结论

  • 按通胀调整后,尽管IMRT、立体定向RT和图像引导使用增加,RO总支出仍下降;而肿瘤总成本因药物支出上升。

研究设计与样本

  • 利用某州级多专科医疗系统在OCM前8个6个月绩效期(PP1-8:2016年7月1日至2020年6月30日)的真实世界数据,识别9898例患者的17157次诊疗,并对2033例接受RT患者的2219次诊疗进行RO支出分析。

主要发现

  • 每次诊疗平均RO支出PP1为6314美元 vs PP8为6664美元(P趋势>.05);按2016年7月消费者价格指数调整后从6314美元降至6215美元。
  • 每次诊疗平均RT分次从PP1的19.2降至PP8的18.6,乳腺癌下降2.1、肺癌下降2.8、女性泌尿生殖系统肿瘤下降3.5。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to use real world data to assess trends in radiation therapy (RT) treatment fractionation and cost under the Oncology Care Model (OCM) through the first 8 performance periods (PPs). METHODS: We identified 17,157 episodes of care from 9898 patients treated at a statewide multispecialty health system through the first 8 6-month PPs (PP1-8: July 1, 2016, to June 30, 2020) of the OCM. Spending was stratified by 10 expenditure domains (eg, Part B/D drugs, radiation oncology [RO], etc), and 21 disease sites were extracted from claims data, from which an analysis of RO expenditures was performed on 2219 episodes from 2033 patients treated with RT. Expenses are expressed in per-beneficiary, per-episode terms. RESULTS: RO expenditures comprised 3% ($14.7M) of total spending over the 8 periods. By primary cancer, the largest RO expenses were for breast ($2.9M; 20%), prostate ($2.9M; 19%), and lung cancer ($2.8M; 13%). For RO, total per-episode average spending remained roughly constant between PP1 ($6314) and PP8 ($6664; Ptrend > .05) and decreased ($6314-$6215) when indexed to the Consumer Price Index for July 2016. Average number of RT fractions per episode decreased from 19.2 in PP1 to 18.6 in PP8; this decrease was most notably seen for breast (-2.1), lung (-2.8), and female genitourinary (-3.5) cancers. Intensity-modulated RT (IMRT) charges accounted for $7.6M (51%) of RT spending and increased 5% from PP1 to 8, whereas conventional external beam RT made up $3.0M (21%) and decreased 8%. Expenses for image guidance ($2.5M; 17%; +2% from PP1-8) and stereotactic RT ($1.3M; 9%; +1%) increased. CONCLUSIONS: In inflation-adjusted terms, total RO expenditures have declined despite greater use of IMRT, stereotactic RT, and image guidance. Conversely, oncology costs have risen because of drug spending. Successful payment models must prioritize high-cost spending areas-including novel drug therapies-while accounting for high-value care and patient outcomes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. De B, Andres G, Bates C, et al. Radiation Therapy Expenditures Through the First 8 Performance Periods of the Oncology Care Model at a Statewide Multispecialty Health System. Int J Radiat Oncol Biol Phys. 2022. PMID: 36427644. doi:10.1016/j.ijrobp.2022.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。